9 Meters Biopharma and Cara Therapeutics tout mid-stage data for gastrointestinal, pruritus studies
While 9 Meters Biopharma is still floundering in the penny stock market, the company is hoping the latest results for its candidate to treat short …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
